1. Insulin resistance
Insulin resistance is the metabolic condition that underlies most cases of fatty liver disease. It occurs when the body’s cells become less responsive to insulin, a hormone that regulates blood sugar levels. To compensate, the pancreas produces more insulin, leading to elevated insulin levels in the bloodstream.
This excess insulin drives the liver to convert more glucose into fat, resulting in increased fat storage within liver cells. Over time, this fat buildup impairs liver function and contributes to the development of non-alcoholic fatty liver disease (NAFLD).
In clinical practice, insulin resistance is often assessed using the HOMA-IR index, which combines fasting insulin and glucose measurements. Addressing insulin resistance through lifestyle changes can significantly reduce liver fat and prevent progression to more severe liver conditions.
2. Visceral fat accumulation
Visceral fat is the fat stored deep around internal organs, including the liver, pancreas, and intestines. Unlike subcutaneous fat, which lies just beneath the skin, visceral fat is metabolically active and releases substances that promote inflammation and insulin resistance.
Notably, people with a normal body weight can still have excessive visceral fat—a condition sometimes called “metabolically obese normal weight.” This hidden fat is a key risk factor for fatty liver disease and cardiovascular problems.
- Increased waist circumference often signals visceral fat accumulation.
- Visceral fat contributes to liver fat buildup by releasing free fatty acids into the portal vein, which directly feeds the liver.
- Excess visceral fat worsens insulin resistance, creating a dangerous feedback loop.
Reducing visceral fat through diet, exercise, and weight management is critical for improving liver health.
3. Chronic low-grade inflammation
Chronic low-grade inflammation is a subtle yet persistent immune response that damages tissues over time. In the context of fatty liver, this inflammation is triggered by excess fat, insulin resistance, and signals from visceral adipose tissue.
Unlike acute inflammation, it does not cause obvious pain or swelling but promotes liver cell injury and fibrosis (scarring). Inflammatory markers such as C-reactive protein (CRP) and ferritin may be elevated in blood tests.
This ongoing inflammation sustains the metabolic disturbances that allow fatty liver disease to progress toward non-alcoholic steatohepatitis (NASH), a more serious liver condition that can lead to cirrhosis.
